

Please amend the following claims as indicated:

- 1) (Withdrawn) A method for delivering a pharmaceutical agent through a membrane, wherein the method comprises applying to said membrane a composition comprising:
 - a) anionic phospholipids;
 - b) a safe and effective amount of the pharmaceutical agent contained within the phospholipids; and
 - c) a fusogenic protein or polypeptide derived from prosaposinin a pharmaceutically acceptable carrier, wherein the concentration of the fusogenic protein or polypeptide is of a sufficient amount to deliver the pharmaceutical agent through the membrane.
- 2) (Withdrawn) The method of claim 2 wherein the concentration of phospholipids are in at least a 10-fold excess, by weight, to that of the fusogenic protein or polypeptide.
- 3) (Withdrawn) The method of claim 2 wherein the pH of the composition is between about 5.5 and 2.
- 4) (Withdrawn) The method of claim 3 wherein the anionic phospholipid is an anionic liposome.
- 5) (Withdrawn) The method of claim 4 wherein the fusogenic protein or polypeptide is associated with the liposome through an electrostatic and hydrophobic interaction.

- 6) (Withdrawn) The method of claim 5 wherein the membrane is selected from the group consisting of dermal and mucosal membranes.
- 7) (Withdrawn) The method of claim 6 wherein the fusogenic protein or polypeptide is selected from the group consisting of saposin A, saposin C, polypeptide analogs, derivatives, homologues, fragments of saposin A and saposin C, and mixtures thereof.
- 8) (Withdrawn) The method of claim 6 wherein the fusogenic protein or polypeptide is saposin C.
- 9) (Withdrawn) The method of claim 6 wherein the fusogenic protein or polypeptide is SEQ. ID. NO. 1.
- 10) (Withdrawn) The method of claim 6 wherein the fusogenic protein or polypeptide is SEQ. ID. NO. 2.
11. (Withdrawn) The method of claim 6 wherein the fusogenic protein or polypeptide is of the formula given by SEQ ID Nos. 3-6.
- 12) (Withdrawn) The method of claim 7 wherein administration of the composition is via a transdermal patch.

13) (Withdrawn) The method of claim 7 wherein the composition is administered either enterally or topically.

14) (Withdrawn) A method for delivering a pharmaceutical agent through either a dermal or mucosal membrane, wherein the method comprises the administration to said membrane of a composition comprising:

- a) anionic liposomes;
- b) a safe and effective amount of the pharmaceutical agent contained within the liposomes; and
- c) saposin C;

in a pharmaceutically acceptable carrier, wherein the concentration of the liposomes are of a sufficient amount to deliver a safe and effective amount of the pharmaceutical agent through the membrane, the pH of the composition is between about 5.5 and 2, and the saposin C is associated with the surface of the liposome through an electrostatic and hydrophobic interaction.

15) (Withdrawn) The method of claim 14 wherein the concentration of the liposomes is in at least a 10-fold excess, by weight, to that of saposin C.

16) (currently amended) A therapeutic phospholipid composition comprising:

- a) an anionic phospholipid;
- b) a safe and effective amount of the pharmaceutical agent contained within the phospholipids; and
- c) a fusogenic protein or polypeptide derived from prosaposin;

in a pharmaceutically acceptable carrier, wherein the ~~concentration of the~~ fusogenic protein or polypeptide is present in a sufficient concentration to deliver the pharmaceutical agent through a biological membrane and the fusogenic protein or polypeptide is associated with the phospholipid through an electrostatic and hydrophobic interaction.

17)(currently amended) The therapeutic phospholipid composition of claim 16 wherein the concentration of anionic phospholipids is in at least a 10-fold excess, by weight, to that of the fusogenic protein or polypeptide.

18)(currently amended) The therapeutic phospholipid composition of claim 17 wherein the pH of the composition is between about 5.5 and 2.

19)(currently amended) The therapeutic phospholipid composition of claim 18 wherein the anionic phospholipid is an anionic liposome.

20)(currently amended) The therapeutic phospholipid composition of claim 19 wherein the biological membrane is selected from the group consisting of dermal and mucosal membranes.

21)(currently amended) The therapeutic phospholipid composition of claim 20 wherein the fusogenic protein or polypeptide is selected from the group consisting of saposin A, and saposin C, ~~polypeptide analogs, derivatives, homologues, fragments of saposin A and saposin C,~~ and mixtures thereof.

22)(currently amended) The therapeutic phospholipid composition of claim 20 wherein the fusogenic protein or polypeptide is saposin C.

23)(currently amended) The therapeutic phospholipid composition of claim 20 wherein the fusogenic protein or polypeptide is SEQ. ID. NO. 1.

24)(currently amended) The therapeutic phospholipid composition of claim 20 wherein the fusogenic protein or polypeptide is SEQ. ID. NO. 2.

25)(currently amended) The therapeutic phospholipid composition of claim 20 wherein the fusogenic protein or polypeptide is selected from the group consisting of those proteins or polypeptides ~~of the formula~~ given by SEQ ID Nos. 3-6.

26)(currently amended) The therapeutic phospholipid composition of claim 21 wherein the composition is formulated as part of a transdermal patch.

27)(currently amended) The therapeutic phospholipid composition of claim 21 wherein the composition is formulated for enteral or topical administration.

28)(currently amended) ~~A phospholipid~~ An anionic liposomal composition used to deliver a pharmaceutical agent through either a dermal or mucosal membrane, wherein the composition comprises:

- a) anionic liposomes;
- b) a safe and effective amount of the pharmaceutical agent contained within the liposomes; and

- c) ~~a fusogenic protein or polypeptide selected from the group consisting of saposin C, polypeptide analogs, derivatives, homologues, fragments of saposin C, and mixtures thereof;~~

in a pharmaceutically acceptable carrier where the pH of the composition is between about 5.5 and 2, wherein the concentration of the saposin C ~~fusogenic protein or polypeptide~~ is of a sufficient amount to deliver the pharmaceutical agent through a biological membrane and the saposin C ~~fusogenic protein or polypeptide~~ is associated with the surface of the liposomes through an electrostatic and hydrophobic interaction.

- 29) (currently amended) The ~~phospholipid~~ anionic liposomal composition of claim 28 wherein the concentration of the anionic liposomes is in at least a 10-fold excess, by weight, to that of saposin C.

- 30) (currently amended) A composition comprising a safe and effective amount of a pharmaceutical agent contained in ~~an~~ anionic liposomes, which are ~~is~~ associated with a prosaposin-derived fusogenic protein or polypeptide via an electrostatic and hydrophobic interaction, wherein the concentration of the fusogenic protein or polypeptide is of a sufficient amount to deliver the pharmaceutical agent through a biological membrane, the composition contained in a pharmaceutically acceptable carrier, wherein the pH of the composition is between about 5.5 and 2.

- 31) (currently amended) The composition of claim 30 wherein the concentration of anionic liposomes is in at least a 10-fold excess, by weight, to that of the fusogenic protein or polypeptide.

- 32) (Original) The composition of claim 31 wherein the biological membrane is selected from the group consisting of dermal and mucosal membranes.
- 33) (currently amended) The composition of claim 32 wherein the fusogenic protein or polypeptide is selected from the group consisting of saposin A, saposin C, ~~polypeptide analogs, derivatives, homologues, fragments of saposin A and saposin C,~~ and mixtures thereof.
- 34) (currently amended) The ~~phospholipid~~ composition of claim 31 wherein the fusogenic protein or polypeptide is saposin C.
- 35) (Original) The composition of claim 31 wherein the fusogenic protein or polypeptide is SEQ. ID. NO. 1.
- 36) (Original) The composition of claim 31 wherein the fusogenic protein or polypeptide is SEQ. ID. NO. 2.
37. (currently amended) The composition of claim 31 wherein the fusogenic protein or polypeptide is selected from the group consisting of those proteins or polypeptides ~~of the formula~~ given by SEQ ID Nos. 3-6.
- 38) (Original) A phospholipid composition used to deliver a pharmaceutical agent through either a dermal or mucosal membrane, wherein the composition comprises:

- a) anionic liposomes;
- b) a safe and effective amount of the pharmaceutical agent contained within the liposomes; and
- c) saposin C;

in a pharmaceutically acceptable carrier, wherein the pH of the composition is between about 5.5 and 2, the concentration of the saposin C is of a sufficient amount to deliver the pharmaceutical agent through the membrane and the saposin C is associated with the surface of the liposome through an electrostatic and hydrophobic interaction.

39) (currently amended) The phospholipid composition of claim 38 wherein the concentration of the anionic liposomes is in at least a 10-fold excess, by weight, to that of saposin C.

40) (currently amended) The polypeptide consisting of SEQ. ID. NO. 1.

41) (currently amended) The polypeptide consisting of SEQ. ID. NO. 2.

42. (currently amended) A compound of the formula consisting of ~~given by~~ SEQ ID Nos. 3-6.

43) (Withdrawn) A method for treating Gauchers Disease wherein the method comprises the administration of a composition comprising:

- a) anionic liposomes;

b) a safe and effective amount of acid beta-glucosidase contained within the liposomes; and

c) saposin C;

in a pharmaceutically acceptable carrier, wherein the pH of the composition between about 5.5 and 2, the concentration of the saposin C is of a sufficient amount to deliver the pharmaceutical agent through the membrane and the saposin C is associated with the surface of the liposome through an electrostatic and hydrophobic interaction.

44) (Withdrawn) The method of claim 43 wherein the concentration of the liposome is in at least a 10-fold excess, by weight, to that of saposin C.